Eiken Chemical : Business Results for the First Nine Months of fiscal year ending March 31, 2022 PDF

Business Results for the First Nine Months of fiscal year ending March 31, 2022

January 28, 2022

EIKEN CHEMICAL CO., LTD

（Code：4549）

■ Consolidated financial highlights

							（Million of yen）
First nine months ending to March 31, 2022 - Consolidated -
		Results		Ratio	YoY change
Net sales	31,831		100.0%	3,283		111.5
（Overseas sales）		6,660		20.9%	1,948		141.3%
Operating profit		6,643		20.9%	1,111		120.1
Ordinary profit	6,740		21.2%	1,084		119.2
Profit attributable to	5,036		15.8%	751		117.5
owners of parent

➢ Net sales and profits increased, reflecting the resumption of a range of medical examinations and screening programs and ongoing demand for the COVID-19 detection kits.

2

■ Sales by Segment -Consolidated-

			（Million of yen）
		First Nine Months	First Nine Months	YoY ratio
		of FY03/2021	of FY03/2022
FIT reagents (OC)	7,045	8,742	124.1%
Immunological and	7,038	7,277	103.4%
serological reagents
Urinalysis test strips	2,577	2,900	112.5%
Microbiological reagents	3,132	3,077	98.2%
Clinical chemistry reagents	466	479	102.8%
Food and environment	1,596	1,679	105.2%
category, equipments
Molecular genetics(LAMP)	4,391	4,680	106.6%
Medical devices/Others	2,299	2,993	130.2%
Total		28,547	31,831	111.5%

3

（Million of yen）

31,831

28,547

8,742

7,045

		7,277
7,038
2,577	2,900
3,132	3,077
479
466
1,679
1,596
4,391	4,680
2,299	2,993
	First Nine Months		First Nine Months
	of FY03/2021		of FY03/2022

(previous year: 602 million yen)

■ Sales by Segment － Molecular genetics(LAMP)

○Sales of the COVID-19 detection kits rose sharply. ○License/patent fee income: 739 million yen.

First nine monthes		Full-year	（Million of yen）

＊ SARS-CoV-2 is the causative virus of COVID19.

6,390

4,3914,680

1,331

1,046

FY03/2020 FY03/2021 FY03/2022

4

Loopamp SARS-CoV-2	Loopamp Realtime Turbidimeter
Detection Kit	LoopampEXIA

Products in a wide range of fields such as medical care, food and environment using our original technology LAMP. TB-LAMP (Tuberculosis Test) received WHO recommendations in 2016 and is currently being sales for developing countries.

■ Sales by Segment － FIT reagents (OC) / Urinalysis test strips

〇FIT reagents： Sales increased due to the resumption of a range of medical examination programs.

〇Urinalysis test strips: Sales increased, reflecting signs of recovery in the medical checkup market

and a rise in sales to Sysmex Corporation.:

FIT reagents (OC)

Urinalysis test strips

（Million of yen）

（Million of yen）

First nine monthes		Full-year

First nine monthes Full-year

10,352 9,632

[4,265] [3,929]

[ ]: Overseas sales

8,245			8,742
		[3,845]
[3,149]	7,045					3,380
		[2,421]				3,340
							2,417	2,577	2,900
	FY03/2020		FY03/2021		FY03/2022			FY03/2020		FY03/2021		FY03/2022

5